Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
Otolaryngologists should be made aware of a newer cause of nasal septal perforations resulting from the more recent antiangiogenic therapy used to treat malignancies. This case describes a 52-year-old white woman who developed a spontaneous nasal septal perforation after given the antiangiogenic drug, bevacizumab, for metastatic ovarian cancer treatment. Bevacizumab is a recently developed monoclonal antibody against vascular endothelial growth factor receptor used to inhibit angiogenesis. The patient was ultimately treated with a nasal septal button with good symptom relief. This case documents the first report in the otolaryngology literature describing this new etiology for nasal septal perforations.
Burkart
Collin M
CM
Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0528, USA.
Grisel
Jedidiah J
JJ
Hom
David B
DB
D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003937:Diagnosis, Differential; D004724:Endoscopy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009300:Nasal Septum / Q000187:drug effects* / Q000473:pathology; D009668:Nose Diseases / Q000139:chemically induced* / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012422:Rupture, Spontaneous; D042461:Vascular Endothelial Growth Factor A
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab